Boston Scientific offers notes for proposed Penumbra deal
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Boston Scientific Corporation (BSX) is offering four series of senior notes and intends to use net proceeds, together with any Euro Notes proceeds, short-term or credit-agreement borrowings and cash on hand, to finance the cash consideration and fees and expenses for its proposed Penumbra acquisition. Any net proceeds not used for those purposes may go to general corporate purposes. At announcement, the proposed acquisition was valued at $374 per share, or approximately $14.5 billion; Penumbra stockholders approved it on May 6, 2026, and closing is expected in early 2027, subject to required regulatory approvals and other customary conditions.
A Special Mandatory Redemption can require repayment at 101% of principal plus accrued and unpaid interest if the acquisition misses its applicable deadline or BSX notifies the trustee it will not proceed; offering proceeds are not escrowed. The notes are senior unsecured obligations. At September 30, 2026, BSX had approximately $11.952 billion of unsecured indebtedness, while certain subsidiaries had approximately $141 million of indebtedness structurally senior to the notes. The notes will not be listed, and no public market currently exists.
Filing Explained
The November 19 supplement is marked preliminary and subject to completion, with principal amounts, interest rates, maturities and estimated net proceeds left blank; as a result, this filing does not establish the size or final pricing of the proposed debt offering.
Key Figures
Key Terms
senior unsecured obligations financial
structurally subordinated financial
Special Mandatory Redemption financial
Change of Control Repurchase Event financial
Treasury Rate financial
contingent payment debt instruments financial
Offering Details
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much is BSX’s proposed acquisition of Penumbra worth?
What happens if BSX’s Penumbra acquisition does not close?
What will BSX use the senior-note proceeds for?
AI-generated analysis. How Rhea-AI works. Not financial advice.
(To Prospectus dated February 18, 2025)
| | | |
Offering Price
to Public(1) |
| |
Underwriting
Discounts |
| |
Proceeds to Us
Before Expenses(1) |
| | | | | | | |||||||||||||||||||||||||||
| | | |
Per Note
|
| |
Total
|
| |
Per Note
|
| |
Total
|
| |
Per Note
|
| |
Total
|
| | | | |||||||||||||||||||||
|
20 Notes
|
| | | | % | | | | | $ | | | | | | % | | | | | $ | | | | | | % | | | | | $ | | | | | | ||||||
|
20 Notes
|
| | | | % | | | | | $ | | | | | | % | | | | | $ | | | | | | % | | | | | $ | | | | | | ||||||
|
20 Notes
|
| | | | % | | | | | $ | | | | | | % | | | | | $ | | | | | | % | | | | | $ | | | | | | ||||||
|
20 Notes
|
| | | | % | | | | | $ | | | | | | % | | | | | $ | | | | | | % | | | | | $ | | | | | | ||||||
| |
BofA Securities
|
| |
Citigroup
|
| |
J.P. Morgan
|
|
| | | | |
Barclays
|
| | | |
| | | |
Page
|
| |||
|
ABOUT THIS PROSPECTUS SUPPLEMENT
|
| | | | S-ii | | |
|
SUMMARY
|
| | | | S-1 | | |
|
THE OFFERING
|
| | | | S-2 | | |
|
RISK FACTORS
|
| | | | S-5 | | |
|
INFORMATION CONCERNING FORWARD-LOOKING STATEMENTS
|
| | | | S-8 | | |
|
USE OF PROCEEDS
|
| | | | S-9 | | |
|
DESCRIPTION OF THE NOTES
|
| | | | S-10 | | |
|
MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES
|
| | | | S-18 | | |
|
CERTAIN ERISA CONSIDERATIONS
|
| | | | S-22 | | |
|
UNDERWRITING
|
| | | | S-24 | | |
|
LEGAL MATTERS
|
| | | | S-30 | | |
|
EXPERTS
|
| | | | S-30 | | |
|
WHERE YOU CAN FIND MORE INFORMATION
|
| | | | S-31 | | |
| | | |
Page
|
| |||
|
ABOUT THIS PROSPECTUS
|
| | | | 1 | | |
|
WHERE YOU CAN FIND MORE INFORMATION
|
| | | | 2 | | |
|
FORWARD-LOOKING STATEMENTS
|
| | | | 3 | | |
|
RISK FACTORS
|
| | | | 4 | | |
|
BOSTON SCIENTIFIC CORPORATION
|
| | | | 5 | | |
|
AMERICAN MEDICAL SYSTEMS EUROPE B.V.
|
| | | | 5 | | |
|
USE OF PROCEEDS
|
| | | | 6 | | |
|
DESCRIPTION OF DEBT SECURITIES
|
| | | | 7 | | |
|
PLAN OF DISTRIBUTION
|
| | | | 19 | | |
|
LEGAL MATTERS
|
| | | | 21 | | |
|
EXPERTS
|
| | | | 21 | | |
Redemption
|
Underwriters
|
| |
Aggregate
Principal Amount of 20 notes |
| |
Aggregate
Principal Amount of 20 notes |
| |
Aggregate
Principal Amount of 20 notes |
| |
Aggregate
Principal Amount of 20 notes |
| ||||||||||||
|
BofA Securities, Inc.
|
| | | $ | | | | | $ | | | | | $ | | | | | $ | | | ||||
|
Citigroup Global Markets Inc.
|
| | | $ | | | | | $ | | | | | $ | | | | | $ | | | ||||
|
J.P. Morgan Securities LLC
|
| | | $ | | | | | $ | | | | | $ | | | | | $ | | | ||||
|
Barclays Capital Inc.
|
| | | $ | | | | | $ | | | | | $ | | | | | $ | | | ||||
|
Total
|
| | | $ | | | | | $ | | | | | $ | | | | | $ | | | | |||
300 Boston Scientific Way
Marlborough, Massachusetts 01752-1234
Attention: Investor Relations
Telephone: (508) 683-5670
Email: BSXInvestorRelations@bsci.com
Subordinated Debt Securities
Guarantees
Subordinated Debt Securities
Guarantees
| | | |
Page
|
| |||
|
ABOUT THIS PROSPECTUS
|
| | | | 1 | | |
|
WHERE YOU CAN FIND MORE INFORMATION
|
| | | | 2 | | |
|
FORWARD-LOOKING STATEMENTS
|
| | | | 3 | | |
|
RISK FACTORS
|
| | | | 4 | | |
|
BOSTON SCIENTIFIC CORPORATION
|
| | | | 5 | | |
|
AMERICAN MEDICAL SYSTEMS EUROPE B.V.
|
| | | | 5 | | |
|
USE OF PROCEEDS
|
| | | | 6 | | |
|
DESCRIPTION OF DEBT SECURITIES
|
| | | | 7 | | |
|
PLAN OF DISTRIBUTION
|
| | | | 19 | | |
|
LEGAL MATTERS
|
| | | | 21 | | |
|
EXPERTS
|
| | | | 21 | | |
300 Boston Scientific Way
Marlborough, Massachusetts 01752-1234
Attention: Investor Relations
Telephone: (508) 683-5670
Email: BSXInvestorRelations@bsci.com